Teva scraps cluster headache program

Teva Pharmaceutical Industries Ltd said on Tuesday it would stop developing its migraine drug, Ajovy, for treating cluster headaches.

The company said the decision was taken after an analysis of late-stage study data showed that the drug was unlikely to meet the main goal of the trial.